Children's Oncology Group's 2023 blueprint for research: Non‐Hodgkin lymphoma

Abstract

Pediatric non‐Hodgkin lymphoma (NHL) includes over 30 histologies (many with subtypes), with approximately 800 cases per year in the United States. Improvements in survival in NHL over the past 5 decades align with the overall success of the cooperative trial model with dramatic improvements in outcomes. As an example, survival for advanced Burkitt lymphoma is now >95%. Major remaining challenges include survival for relapsed and refractory disease and long‐term morbidity in NHL survivors. Langerhans cell histiocytosis (LCH) was added to the NHL Committee portfolio in recognition of LCH as a neoplastic disorder and the tremendous unmet need for improved outcomes. The goal of the Children’ Oncology Group NHL Committee is to identify optimal cures for every child and young adult with NHL (and LCH). Further advances will require creative solutions, including engineering study groups to combine rare populations, biology‐based eligibility, alternative endpoints, facilitating international collaborations, and coordinated correlative biology.

B–NHL Cases in a Tertiary Pediatric Hematology—Oncology Department: A 20-Year Retrospective Cohort Study

“…In our cohort, only 73% presented with elevated LDH, and its values did not predict adverse outcomes. Beyond LDH, low albumin has been associated with treatment-related mortality, but a robust prognostic biomarker in pediatric B-NHL is lacking [20,21]. The literature reports support the prognostic value of beta-2-microglobulin levels on NHL survival rates [22].…”

B-lymphoblastic Lymphoma Isolated to the Testes: A Case Report and Review of Literature

“…Lymphoblastic lymphoma comprises approximately 25% of pediatric non-Hodgkin lymphoma (NHL), of which only 20-30% is B-lymphoblastic lymphoma (B-LLy), while the remaining 70-80% of cases are Tlymphoblastic lymphoma (T-LLy) [1]. Given that only about 800 cases of pediatric NHL are diagnosed in the United States each year, B-LLy is quite rare, with an estimated 40-60 cases of B-LLy expected to occur annually in the United States [1].…”

“…Lymphoblastic lymphoma comprises approximately 25% of pediatric non-Hodgkin lymphoma (NHL), of which only 20-30% is B-lymphoblastic lymphoma (B-LLy), while the remaining 70-80% of cases are Tlymphoblastic lymphoma (T-LLy) [1]. Given that only about 800 cases of pediatric NHL are diagnosed in the United States each year, B-LLy is quite rare, with an estimated 40-60 cases of B-LLy expected to occur annually in the United States [1]. B-LLy is distinguished from the morphologically identical and far more common B-lymphoblastic leukemia by the presence of less than 25% lymphoblasts in the bone marrow, regardless of nodal or extra-nodal involvement [2].…”

A Systematic Review on Childhood Non-Hodgkin Lymphoma: An Overlooked Phenomenon in the Health and Research Sector of Bangladesh

“…In children under the age of 15, NHL is the fifth most common type of pediatric cancer. Pediatric NHL, a malignancy that primarily affects individuals in their childhood and early adulthood, has emerged as a significant issue in the United States, with around 800 new cases reported annually and an incidence rate varying between 10 and 20 occurrences per one million individuals [7]. In developed nations, it accounts for about 7% of pediatric cancer cases [8].…”